We spoke to Professor Hugh Calkins (Nicholas J. Fortuin M.D. Professor of Cardiology, Director, Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, MD, USA) at Heart Rhythm 2019 about upcoming developments in atrial fibrillation (AF) ablation and his thoughts on the use or the discontinuation of anticoagulants in patients without recurrence after AF ablation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Hugh Calkins is a consultant for and has received honoraria from Biosense Webster, Medtronic, Abbott, Boston Scientific and Boehringer Ingelheim.
1. What developments should we expect to see in atrial fibrillation (AF) ablation over the next few years? (0:09)
2. What are your thoughts on the use versus the discontinuation of anticoagulants in patients without recurrence of disease after AF ablation? (0:53)
3. What are your key take-home messages from Heart Rhythm 2019? (2:02)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
ESC Congress 2023 Amsterdam: David Conen, COP-AF trial
The COP-AF trial looked at the use of anti-inflammatory colchicine in patients undergoing major noncardiac thoracic surgery and reducing risk of cardiovascular complications, especially perioperative atrial fibrillation and myocardial injury after noncardiac surgery (MINS). We spoke to Prof. David Conen (Population Health Research Institute, Hamilton, ON, Canada), principle investigator of COP-AF and presenter at the […]
World Heart Rhythm Week: Considerations and challenges in arrhythmia
It’s World Heart Rhythm Week 2023! Learn about key considerations for managing and treating arrhythmias, ongoing research and the importance of seeking medical advice for syncope.
Bruce Wilkoff, EHRA 2023: The AdaptResponse trial, synchronized left ventricular pacing for heart failure with left bundle branch block
The AdaptResponse trial was designed to assess two methods of restoring resynchronization to the heart in patients with heart failure with left bundle branch block. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the design of the AdaptResponse trial, the outcomes as well as the clinical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!